Moser Darla K, Schoonover Mike J, Holbrook Todd C, Payton Mark E
Department of Veterinary Clinical Sciences, Oklahoma State University, Stillwater, Oklahoma.
Department of Statistics, Oklahoma State University, Stillwater, Oklahoma.
Vet Surg. 2016 Oct;45(7):851-858. doi: 10.1111/vsu.12521. Epub 2016 Aug 11.
To determine the effect of volume of amikacin perfusate for intravenous regional limb perfusion (IVRLP) via the cephalic vein in standing, sedated horses on (1) amikacin concentrations in the synovial fluid of the radiocarpal joint (RCJ) and distal interphalangeal joint (DIPJ) and, (2) amikacin concentration in the systemic circulation, and (3) regional intravenous pressure.
Randomized cross-over design.
Six adult horses.
Each horse received IVRLP using 4 perfusate volumes (10, 30, 60 & 120 ml) in random order, after a minimum of 1 week washout. After application of a pneumatic tourniquet, IVRLP with 1 g of amikacin in 0.9% NaCl was performed. Synovial fluid from the RCJ and DIPJ, and systemic and regional venous blood were sampled, and regional blood pressure was measured, immediately before perfusion (time 0), and 15 and 30 minutes after perfusion but before tourniquet release.
No difference was observed in the mean amikacin concentration of synovial fluid for the 4 perfusate volumes (P>.09). For all volumes, mean amikacin concentration for DIPJ synovial fluid was higher than for RCJ (P<.0001). The mean amikacin concentration in DIPJ synovial fluid was therapeutic for resistant pathogens using the 10, 60, and 120 mL volumes but the mean amikacin concentration for RCJ synovial fluid was not therapeutic for resistant pathogens with any perfusate volume. All volumes resulted in an immediate increase in mean regional intravascular pressure after perfusion (P<.0001) but was not different across the 4 perfusate volumes.
Cephalic IVRLP of 1 g of amikacin diluted to a volume of 10-120 mL with 0.9% NaCl will achieve amikacin concentrations therapeutic for resistant pathogens in the synovial fluid from the DIPJ. Concentrations below therapeutic levels for resistant pathogens are reached in the synovial fluid from the RCJ.
确定在站立、镇静的马匹中,通过头静脉进行静脉区域肢体灌注(IVRLP)时,阿米卡星灌注液体积对(1)桡腕关节(RCJ)和远侧指间关节(DIPJ)滑液中阿米卡星浓度、(2)体循环中阿米卡星浓度以及(3)区域静脉压力的影响。
随机交叉设计。
6匹成年马。
每匹马在至少1周的洗脱期后,以随机顺序接受使用4种灌注液体积(10、30、60和120毫升)的IVRLP。应用气动止血带后,用1克阿米卡星溶于0.9%氯化钠溶液中进行IVRLP。在灌注前(时间0)以及灌注后15和30分钟但在松开止血带之前,采集RCJ和DIPJ的滑液、体循环和区域静脉血样,并测量区域血压。
4种灌注液体积的滑液中阿米卡星平均浓度未观察到差异(P>0.09)。对于所有体积,DIPJ滑液的阿米卡星平均浓度高于RCJ(P<0.0001)。使用10、60和120毫升体积时,DIPJ滑液中的阿米卡星平均浓度对耐药病原体具有治疗作用,但对于任何灌注液体积,RCJ滑液中的阿米卡星平均浓度对耐药病原体均无治疗作用。所有体积在灌注后均导致平均区域血管内压力立即升高(P<0.0001),但在4种灌注液体积之间无差异。
将1克阿米卡星用0.9%氯化钠溶液稀释至10 - 120毫升体积进行头静脉IVRLP,可使DIPJ滑液中阿米卡星浓度达到对耐药病原体的治疗水平。RCJ滑液中达到的浓度低于对耐药病原体的治疗水平。